GTG Unveils Comprehensive Cancer Risk Test

May 29, 2024

Genetic Technologies Limited (ASX: GTG) has launched a groundbreaking geneType Comprehensive Risk Assessment test, covering 100% of women at risk for breast and ovarian cancer. Available to women over 30, this test evaluates both hereditary and sporadic cancer risks. Introduced at the "Know Your Risk" event in California, co-hosted by renowned figures like Dr. Kristi Funk, the test is seen as a major advancement in preventive healthcare.

GTG's CEO, Simon Morriss, emphasized the test's potential to transform women's health by enabling precise risk assessments and early interventions. GTG has also prepared for high demand by establishing an automated lab in the U.S. capable of processing up to 100,000 tests monthly. This innovation aims to significantly improve early cancer detection and outcomes for women.

 

 

 

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com